clinical trial · NCT07284875
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Kailera·phase3·recruiting·n = 2,340
ObesityOverweightRibupatidePlacebo
brief summary
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
started
Dec 18, 2025
primary completion
Feb 1, 2028
completion
Mar 1, 2028
last updated
Sep 3, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol